Abstract. Prostate cancer (PCa) is the second most common cancer amongst males worldwide. In the current study, microarray datasets GSE3325 and GSE6919 from the Gene Expression Omnibus database were screened to identify candidate genes that are associated with the progression of PCa. A total of 273 differentially expressed genes (DEGs) were identified, which included 173 downregulated genes and 100 upregulated genes, and a protein-protein interaction network was constructed using Search Tool for the Retired of Interacting Genes. The enriched functions and pathways of the identified DEGs included cell adhesion, the negative regulation of cell proliferation, protein binding and focal adhesion. A total of 8 hub genes were identified, of which PDZ binding kinase, Krüppel-like factor 4, collagen type X α-1 chain, RAP1A and RAP39B were indicated to be associated with the progression and recurrence of PCa. In conclusion, the DEGs and hub genes identified in the present study may aid in determining the molecular mechanisms associated with PCa carcinogenesis and progression.

Introduction

Prostate cancer (PCa) is the second most common type of cancer among men globally, and constitutes ~15% of all cancer diagnoses worldwide (1). Digital rectal examination, measurement of the serum level of prostate specific antigen (PSA) and biopsy from a prostate transrectal ultrasonography are the most common diagnostic tools for PCa (2). Additionally, with advances in genetic analysis, alterations have been identified in a number of gene regions in patients with PCa, including prostate antigen 3, androgen-dependent transmembrane serine 2 and S-transferase P1 (3-5). However, genetic analysis exhibits a low specificity and can increase the number of unnecessary biopsies performed without reducing patient mortality (6). Previous studies have associated the tribbles pseudokinase 1 gene with the development of a number of tumors, including colorectal leukemia and hepatocellular cancers (7-9). It has been shown that transmembrane protease, serine 2:ETS-related gene (TMPRSS2:ERG) fusion is associated with diagnosing PCa in urine samples and DNA-based molecular templates (10). However, due to the lack of effective diagnostic methods during the early stages of the disease, the mortality rate of PCa remains high (10). Therefore, it is crucial to understand the molecular mechanisms associated with PCa carcinogenesis, proliferation and recurrence.

Microarray technology and bioinformatics analysis led to the identification of 273 differentially expressed genes (DEGs) and functional pathways in the carcinogenesis and progression of PCa. In the current study, two mRNA microarray datasets from Gene Expression Omnibus (GEO) were analyzed to identify DEGs between PCa tissues and non-cancerous tissues. Subsequently, the molecular mechanisms of PCa carcinogenesis and progression were investigated using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and protein-protein interaction (PPI) network analyses. In conclusion, a total of 273 DEGs and 8 hub genes were identified in the current study, and these genes may be candidate biomarkers for PCa.
**Enrichment analysis of DEGs.** The Database for Annotation, Visualization and Integrated Discovery (DAVID; version 6.7; http://david.ncifcrf.gov) (15), which provides functional annotation information of genes and proteins, was used to perform DEG analysis of KEGG pathway enrichment (16) and GO annotation (17). P<0.05 was set as the threshold value.

**Module analysis and construction of the PPI network.** The Search Tool for the Retrieval of Interacting Genes (version 10.0; http://string-db.org) (18), which offers comprehensive information on PPIs, was used to create the PPI network. The molecular interaction networks were visualized using Cytoscape (version 3.4.0; https://cytoscape.org/) (19). The Molecular Complex Detection (MCODE) (version 1.4.2) of Cytoscape was used to identify densely connected regions (20). The PPI networks were visualized using Cytoscape software. The hub genes and the most significant module in the PPI networks were identified using MCODE.

**Hub genes selection and analysis.** The hub genes were selected and their co-expression genes were analyzed using cBioPortal (http://www.cbioportal.org) (21). Hierarchical clustering of hub genes was constructed using the University of California, Santa Cruz Cancer Browser (http://genome-cancer.ucsc.edu) (22). The overall survival and disease-free survival analyses of hub genes (the cutoff was the median expression value) were performed using Kaplan-Meier analysis in cBioPortal. The hazard ratio (HR) with 95% confidence intervals and log-rank P-value was also computed. The expression of PDZ binding kinase (PBK) and Krüppel-like factor 4 (KLF4) in cancer tissues were analyzed and presented using the online database Serial Analysis of Gene Expression (SAGE; http://www.ncbi.nlm.nih.gov/SAGE) (23). The relationship between expression patterns and tumor-node-metastasis (TNM) stage, Gleason grade and recurrence status were analyzed using the online database Oncomine (http://www.oncomine.com) (24).

**Results**

**Identification of DEGs in PCa.** After standardization of the microarray results, a total of 1,024 DEGs in GSE6919 and 2,371 DEGs in GSE3325 were identified. The overlap between the 2 datasets contained 273 genes, as presented in Fig. 1A, consisting of 173 downregulated genes and 100 upregulated genes in PCa tissues.

**PPI network and module analysis.** The PPI network of DEGs (Fig. 1B) and the most significant module were identified using Cytoscape (Fig. 1C). The functional analyses of DEGs demonstrated that genes in this module were mainly enriched in nucleotide binding, small molecule binding, focal adhesion and the regulation of the actin cytoskeleton (Table I).

**Functional enrichment analyses of DEGs.** Functional and pathway enrichment analyses of DEGs were performed using DAVID. GO analysis revealed that the biological processes of DEGs were significantly enriched in cell adhesion, negative regulation of cell proliferation, cell division and extracellular matrix organization (Table II). Molecular functions of DEGs were enriched in protein binding, GTP binding, mannose-binding, chromatin binding and chromatin binding (Table II). Cell components enriched with DEGs included the nucleus, cytoplasm, perinuclear region of the cytoplasm and focal adhesion (Table II). KEGG pathway analysis revealed that DEGs were mainly enriched in focal adhesion, regulation of the actin cytoskeleton, tight junction, coagulation cascades and gap junctions.

**Analyses of the 8 hub genes.** In the present study, a total of 8 hub genes were identified and these hub genes were presented in Table III. The criteria for selection were as follows: MCODE scores >5, degree cut-off=2, node score cut-off=0.2, Max depth=100 and k-score=2. Among the 8 genes, PBK, RAP1A, GNAS and RAB39B were upregulated, while COPZ2, KLF4, BACE1 and COL12A1 were downregulated A network of the hub genes and their co-expression genes were analyzed using the cBioPortal online platform (Fig. 2A). Hierarchical clustering demonstrated that the hub genes could differentiate PCa samples from noncancerous samples (Fig. 2B). Subsequently, the overall survival analysis of the hub genes was performed using a Kaplan-Meier curve analysis. Patients with PCa and PBK, RAP1A, GNAS, coatamer protein complex subunit ζ 2 (COPZ2), β-secretase 1 (BACE1) and collagen type XII α-1 Chain (COL12A1) upregulation demonstrated decreased overall survival (Fig. 3A). Patients with PCa and PBK, RAP1A, GNAS, COPZ2, BACE1 and COL12A1 upregulation exhibited decreased disease-free survival (Fig. 3B). Additionally, RAB39B and KLF4 upregulation was associated with increased overall survival and disease-free survival. Based on the above survival analysis, PBK and KLF4 were identified to serve important roles in the carcinogenesis or progression of PCa. Oncomine analysis of cancer and normal tissue revealed that PBK and KLF4 were significantly over-expressed in PCa in the different datasets (Fig. 4A and B). In the Taylor prostate of Oncomine dataset, the increased mRNA levels of PBK were associated with TNM stage, Gleason grade and recurrence status (Fig. 5A). In the Tatulippe prostate of Oncomine dataset, decreased KLF4 mRNA levels were associated with TNM stage, Gleason grade and recurrence status (Fig. 5A and B). PBK gene expression in metastatic tissue was higher compared with primary tumor and solid tissue normal via Oncomine (Fig. 6).

**Discussion**

Previous studies have demonstrated that the TMPRSS2:ERG fusion is significantly associated with the diagnosis of PCa (25-27). Promoter hypermethylation and downregulated expression of glutathione peroxidase 3 have been observed in a variety of cancer types, including thyroid cancer, hepatocellular carcinoma and PCa (10,26,27). Yu et al (28) identified an association between Piwi-like protein 2 (PIWIL2) gene expression and metastatic PCa. Potential markers for use in the diagnosis and treatment of PCa, which exhibit high efficiency, are urgently required. To increase understanding of the molecular mechanisms of candidate genes, GO, KEGG and PPI analyses were performed. In the current study, the epigenetic and genetic mechanisms in PCa were assessed using microarray technology.
A total of two mRNA microarray datasets were selected. A total of 273 DEGs were identified, including 173 downregulated genes and 100 upregulated genes. The interactions of DEGs were investigated using GO and KEGG analyses. DEGs were found to be enriched in focal adhesion, regulation of the actin cytoskeleton, tight junctions, coagulation cascades and gap junctions. However, other studies (29,30) have demonstrated that DEGs were enriched in a number of functional terms, including cellular response to bone morphogenetic protein (BMP) stimulus, response to BMP, extracellular region and pathways that are associated with transforming growth factor-β signaling. GO enrichment analysis revealed that changes in the most significant modules were enriched in nucleotide binding, nucleoside phosphate binding, small molecule binding and cytoskeletal protein binding, while changes in KEGG were mainly enriched in focal adhesion and regulation of the actin cytoskeleton.

A total of 8 DEGs were selected as hub genes. The criteria for selection were as follows: MCODE scores >5, degree cut-off=2, node score cut-off=0.2, Max depth=100 and k-score=2. Among the 8 genes, PBK, RAP1A, GNAS and RAB39B were upregulated, while COPZ2, KLF4, BACE1 and COL12A1 were downregulated. PBK and KLF4 were identified to be important genes in the present study. PBK is highly homologous to mitogen-activated protein kinase (31,32). By virtue of target utilization, PBK has been revealed to influence growth and differentiation (33-36). PBK is expressed in the outer cell layer of seminiferous tubules in primary spermatocytes (37), and is often increased in a number of human cancer types from different tissue

| Pathway ID     | Pathway description                     | Count in gene set | FDR       |
|----------------|-----------------------------------------|-------------------|-----------|
| GO:0000166     | Nucleotide binding                      | 6                 | 0.003     |
| GO:1901265     | Nucleoside phosphate binding            | 6                 | 0.003     |
| GO:0036094     | Small molecule binding                  | 6                 | 0.004     |
| GO:0008092     | Cytoskeletal protein binding            | 5                 | <0.001    |
| hsa04510       | Focal adhesion                          | 8                 | 0.007     |
| hsa04810       | Regulation of actin cytoskeleton        | 8                 | 0.008     |

**GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially expressed genes; FDR, false discovery rate.**

| Term            | Description                                      | Count in gene set | P-value   |
|-----------------|--------------------------------------------------|-------------------|-----------|
| GO:0007155      | Cell adhesion                                    | 12                | 0.049     |
| GO:0008285      | Negative regulation of cell proliferation        | 11                | 0.044     |
| GO:0051301      | Cell division                                    | 10                | 0.050     |
| GO:0030308      | Negative regulation of cell growth               | 7                 | 0.006     |
| GO:0030198      | Extracellular matrix organization                 | 7                 | 0.051     |
| GO:0005634      | Nucleus                                           | 99                | <0.001    |
| GO:0005737      | Cytoplasm                                         | 93                | <0.001    |
| GO:0048471      | Perinuclear region of cytoplasm                  | 17                | 0.010     |
| GO:0005925      | Focal adhesion                                    | 16                | <0.001    |
| GO:0009986      | Cell surface                                      | 14                | 0.033     |
| GO:0005515      | Protein binding                                   | 147               | <0.001    |
| GO:0005525      | GTP binding                                       | 13                | 0.007     |
| GO:0003682      | Chromatin binding                                 | 12                | 0.019     |
| GO:0019901      | Protein kinase binding                            | 11                | 0.035     |
| hsa04510        | Focal adhesion                                    | 11                | 0.007     |
| hsa04810        | Regulation of actin cytoskeleton                  | 9                 | 0.008     |
| hsa04530        | Tight junction                                    | 6                 | 0.003     |
| hsa04540        | Gap junction                                      | 6                 | 0.005     |

**GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially expressed genes.**
sources (38,39). However, the function of PBK has not yet been fully determined. In a previous study, the immunohistochemical expression of PBK/T-LAK cell-originated protein kinase (TOPK) was revealed to be significantly associated with human bladder cancer, and was identified as a novel diagnostic biomarker for this disease (40). In the present

| No. | Gene symbol | Full name                                  | Function                                                                                       |
|-----|-------------|--------------------------------------------|------------------------------------------------------------------------------------------------|
| 1   | PBK         | PDZ binding kinase                         | Active lymphoid cells and support testicular functions; over expression of this gene has been implicated in tumorigenesis |
| 2   | RAP1A       | Member of RAS oncogene family              | Affect cell proliferation and adhesion, and may play a role in tumor malignancy                |
| 3   | GNAS        | Member of RAS oncogene family              | The encoded protein regulates signaling pathways that affect cell proliferation and adhesion   |
| 4   | COPZ2       | Coatomer protein complex subunit ζ 2       | This gene encodes a member of the adaptor complexes small subunit family                      |
| 5   | KLF4        | Krüppel-like factor 4                      | Control the G1-to-S transition of the cell cycle                                              |
| 6   | BACE1       | β-secretase 1                              | This gene encodes a member of the peptidase A1 family of aspartic proteases                   |
| 7   | COL12A1     | Collagen type XII α 1 chain                | Modify the interactions between collagen I fibrils and the surrounding matrix                 |
| 8   | RAB39B      | Member RAS oncogene family                 | Encodes a member of the Rab family of proteins                                               |

Figure 1. Venn diagram, PPI network and the most significant module of DEGs. (A) DEGs were selected with a fold change >2 and P-value <0.01. The 2 datasets showed an overlap of 273 genes. (B) PPI network of DEGs constructed using Cytoscape. (C) Most significant module with 20 nodes and 100 edges. Upregulated genes are marked in light red; downregulated genes are marked in light blue. DEGs, differentially expressed genes; PPI, protein-protein interaction.
Figure 2. Interaction network and biological process analysis of the hub genes. (A) Hub genes and co-expression genes were analyzed using cBioPortal. Nodes with bold black outline represent hub genes. Nodes with thin black outline represent the co-expression genes. (B) Hierarchical clustering of hub genes. The samples under the red bar are non-cancerous samples and the samples under the blue bar are PCA samples.

Figure 3. Correlation of expression of individual hubs genes survival. (A) Overall survival and (B) disease-free survival analyses of hub genes were performed using cBioPortal online platform. P<0.05 was considered statistically significant.
Figure 4. Oncomine analysis of cancer vs. normal tissue of PBK and KLF4. Heat maps of (A) PBK and (B) KLF4 gene expression in clinical PCA carcinoma samples vs. normal tissues. PBK, PDZ binding kinase; KLF4, Krüppel-like factor 4.

Table 1. Median rank and p-value for PBK and KLF4 gene expression.

| Gene | Median rank | P-value | Fold-change |
|------|-------------|---------|-------------|
| PBK  | 211.5       | 0.004   | 14.415      |
| KLF4 | 483.0       | <0.001  | 14.415      |

Figure 5. Relationship between the PBK, KLF4 and clinicopathological features. Association between the expression of (A) PBK and (B) KLF4 and TNM stage, Gleason grade and recurrence status. PBK, PDZ binding kinase; KLF4, Krüppel-like factor 4; TNM, tumor-node-metastasis.

Figure 5. Relationship between the PBK, KLF4 and clinicopathological features. Association between the expression of (A) PBK and (B) KLF4 and TNM stage, Gleason grade and recurrence status. PBK, PDZ binding kinase; KLF4, Krüppel-like factor 4; TNM, tumor-node-metastasis.
study, the PPI network revealed that PBK directly interacted with cyclin-dependent kinase 1, Rac GTPase-activating protein 1, baculoviral IAP repeat containing 5 and protein regulator of cytokinesis 1, indicating a key role for PBK in PCa. The expression of PBK was subsequently assessed. Gene upregulation in PBK were associated with reductions in overall and disease free survival. Additionally, the KLF4 upregulation was significantly associated with increased overall survival and disease-free survival.

High levels of PBK were associated with advanced stages, Gleason score ≥8 and recurrence (41). Additionally, PBK was significantly increased in PCa (P=0.001), and the expression was higher in the Gleason high-scoring group compared with the low-scoring group (P=0.001) (41). PBK, Gleason score and pathological stage are independent predictors of PCa recurrence, and PBK has been indicated to be significantly associated with survival of no biochemical recurrence (42). As an important mitotic kinase, PBK has been reported to exhibit a close association with patient clinical characteristics (43). The current study indicated that higher mRNA levels of PBK were associated with TNM stage, Gleason grade and recurrence status, demonstrating the vital roles of PBK in the carcinogenesis and progression of PCa. PBK gene expression in metastatic tissue was higher compared with primary tumor and solid tissue normal tissue, and PBK has been indicated to serve an important role in mitosis (43). PBK expression and phosphorylation are significantly increased during cell mitosis (44). Previously, a knock-out study of TOPK revealed that PBK can affect spindle formation (36). When PBK is inhibited during mitosis, the spindle (especially the central part) in mitosis and the subsequent cells become blurred (44). The pulp division cannot be completed smoothly and the cells will subsequently split out of the multinucleated cells. Therefore, PBK has been identified to be associated with the regulation of proliferation and cell cycle changes in malignant tumor cells, and has also been revealed to promote tumor cell transformation (33).

KLF4 is a member of the Krüppel-like zinc finger transcription factor family, which serves a role in regulating important processes, including cell proliferation, differentiation and embryo development (36). They are also associated with numerous human cancer types, including gastrointestinal, bladder and lung cancers (33,36,45). A number of KLF4 targeting genes are also biomarker transcription factors in the endothelial-mesenchymal transition (EMT) process (45). Additionally, a previous study indicated that the expression of E-cadherin and α-catenin in the KLF4 overexpression treatment group was significantly higher compared with the control group, while the mesenchymal cell marker vimentin and the expression of vascular endothelial growth was significantly lower compared with the control group (46). It has been shown that KLF4 protein is negatively associated with clinical stages in patients with meningioma, and it promotes or inhibits the EMT process by acting on transcription factors (46). The transcription factor KLF4 in PCa cells promotes the migration and invasion of EMT and tumor cells in vitro (47). These results are consistent with the results of the current study, which indicated that lower mRNA levels of PBK were associated with TNM stage, Gleason grade and recurrence status. KLF4 was also indicated to be downregulated in PCa tissue with metastases. Furthermore, the stable knockdown of KLF4 expression in PCa cells has been identified to upregulate the expression of epithelial-related gene E-cadherin and downregulate the expression of a variety of mesenchymal-associated genes in vitro, and has been revealed to serve a role in the inhibition of tumor cell migration and invasion (48). Katz et al (49) demonstrated that the expression of KLF4 in tumor tissues was significantly decreased in patients with PCa in the USA, and that the upregulation of KLF4 inhibited tumor migration and invasion. Shah et al (50) identified a positive feedback loop control between KLF4 and the androgen receptor, and revealed that the inhibition of KLF4 expression in prostatic adenocarcinoma cells can inhibit the occurrence of EMT in vitro and serve a role in inhibiting tumor cell migration and invasion. It has also been indicated that KLF4 can serve the role as an oncogene or tumor suppressor gene in a number of cellular environments (50).

In conclusion, a total of 273 DEGs and 8 hub genes were identified as potential novel diagnostic biomarkers for PCa. The current study identified 2 genes associated with PCa progression, including PBK and KLF4. However, the current study is performed based on bioinformatics methods and no experiments were performed to confirm these conclusions. Therefore, further experimental study is required to support the results gained from the current analysis.
Acknowledgements

Not applicable.

Funding

The present study was supported by Special Projects for Key R&D and Promotion (Science and Technology Breakthrough) of Henan Department of Science and Technology (grant no. 192102310109).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

SL, WBX and JH conceived and designed the study, and the experiments were performed by SL. SL, JH and WBX analyzed the data and wrote the manuscript. The original text was drafted and modified by SL and WBX. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: 359-386, 2015.
2. Roobol MJ, Steyerberg EW, Kranse R, Wollters T, van den Bergh RCN, Bangma CH and Schröder FH: A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 57: 79-85, 2010.
3. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N and Isaacs WB: DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59: 5975-5979, 1999.
4. Tomlins SA, Rhodes DR, Perner S, Mehra R, Dhanasekaran SM, Michalec S, Shah RB, Choudhary U, Monzon FA, Becich MJ, et al: Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406, 2005.
5. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liiu L, McDonald C, Hofer R, Finkielstein S, et al: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790-2799, 2004.
6. Gatter L, Cope L, Bostad BM and Izzizary RA: Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315, 2004.
7. Huang DW, Sherman BT, Tan Q, Collins JR, Alvod WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID gene functional classification tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8: R183, 2007.
8. Kanehisa M: The KEGG database. Novartis Found Symp 247: 91-103, 119-128, 244-252, 2002.
9. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet 25: 25-29, 2000.
10. Smoot ME, Ono K, Ruskenshui J, Wang PL and Ideker T: Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 27: 431-432, 2011.
11. Bandettini WP, Killman P, Mancini C, Booker OJ, Vasa S, Leung SW, Wilson JR, Shanbhag SM, Chen MY and Arae AE: MultiContrast delayed enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: A clinical validation study. J Cardiovasc Magn Reson 14: 83, 2012.
12. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Kuefer R, Sun XW, Varambally S, Caio X, Tchinda J, Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648, 2005.
13. Epstein JI and Sidransky D: Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancr Inst 95: 1634-1637, 2003.
14. Roessler S, Jia HL, Budhu A, Forgues M, Li HJ, Lee JS, Wargotz AE, et al: KeY BioMarKerS in ProSTaTe cancer. Cancer Discov 2: 401-404, 2012.
15. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM and Haussler D: The human genome browser at UCSC. Genome Res 12: 996-1002, 2002.
16. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, et al: Gene expression patterns in human liver cancers. Mol Biol Cell 13: 1929-1939, 2002.
17. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Torgerisson SS, Sun Z, Tang YZ, Qin LX and Wang XW: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70: 10202-10212, 2010.
18. Warmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzarfero V, Bruix J, et al: Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45: 938-947, 2007.
19. Zhao H, Li J, Li X, Han C, Zhang Y, Zheng L and Guo M: Silencing GPX3 expression promotes tumor metastasis in human thyroid cancer. Curr Protein Pept Sci 16: 316-321, 2015.
20. Cao S, Yan B, Lu Y, Zhang G, Li J, Zhai W, Gao W and Zhang S: Methylation of promoter and expression silencing of GPX3 gene in hepatocellular carcinoma tissue. Cancer 70: 155-160, 2015.
21. Yu YP, Yu G, Tseng G, Cieply K, Nelson J, Defrances M, Zarnegar R, Michalopoulos G and Luo JH: Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 67: 8043-8050, 2007.
22. Elman GM and Crosson KL: Cell adhesion molecules: Implications for a molecular histology. Annu Rev Biochem 60: 155-190, 1991.
30. Fang E, Zhang X, Wang Q and Wang D: Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach. Cancer Biomark 20: 553-561, 2017.
31. Yang Y, Zhang X, Song D and Wei J: Piwi2 modulates the invasion and metastasis of prostate cancer by regulating the expression of matrix metalloproteinase-9 and epithelial-mesenchymal transitions. Oncol Lett 10: 1735-1740, 2015.
32. Gaudet S, Branton D and Lue RA: Characterization of PDZ binding kinase, a mitotic kinase. Proc Natl Acad Sci USA 97: 5167-5172, 2000.
33. Abe Y, Matsumoto S, Kito K and Ueda N: Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-activated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem 275: 21525-21531, 2000.
34. Zhang C, Habets G and Bollag G: Interrogating the kinome. Nat Biotechnol 29: 981-983, 2011.
35. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, Ruths D, Tseng JT, Yu S, Yu Q, et al: Kinome siRNA-phospho-proteomic screen identifies networks regulating AKT signaling. Oncogene 30: 4567-4577, 2011.
36. Matsumoto S, Abe Y, Fujibuchi T, Takeuchi T, Kito K, Ueda N, Shigemoto K and Gyo K: Characterization of a MAPKK-like protein kinase TOPK. Biochem Biophys Res Commun 325: 997-1004, 2004.
37. Park JH, Nishidate T, Nakamura Y and Katagiri T: Critical roles of T-LAK cell-activated protein kinase in cytokinesis. Cancer Sci 101: 403-411, 2010.
38. Fujibuchi T, Abe Y, Takeuchi T, Ueda N, Shigemoto K, Yamamoto H and Kito K: Expression and phosphorylation of TOPK during spermatogenesis. Dev Growth Differ 47: 637-644, 2005.
39. Park JH, Lin ML, Nishidate T, Nakamura Y and Katagiri T: PDZ-binding kinase/T-LAK cell-activated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 66: 9186-9195, 2006.
40. Singh PK, Srivastava AK, Dalela D, Rath SK, Goel MM and Bhatt ML: Expression of PDZ-binding kinase/T-LAK cell-activated protein kinase (PBK/TOPK) in human urinary bladder transitional cell carcinoma. Immunobiology 219: 469-474, 2014.
41. Kim DJ, Li Y, Reddy K, Lee MH, Kim MO, Cho YY, Lee SY, Kim JE, Bode AM and Dong Z: Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res 72: 3060-3068, 2012.
42. Sun H, Zhang L, Shi C, Hu P, Yan W, Wang Z, Duan Q, Lu F, Qin L, Lu T, et al: TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer. Oncotarget 6: 12392-12404, 2015.
43. Chen JH, Fang SM and Liang YK: Expression and clinical significance of PBK in prostate cancer tissues. Guangzhou Pharm 48: 1000-8535, 2017.
44. Simons-Evelyn M, Bailey-Dell K, Toretsky JA, Ross DD, Fenton R, Kalvakolanu D and Rapoport AP: PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt’s lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis 27: 825-829, 2001.
45. Simons-Evelyn M, Bailey-Dell K, Toretsky JA, Ross DD, Fenton R, Kalvakolanu D and Rapoport AP: PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt’s lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis 27: 825-829, 2001.
46. Wei D, Gong W, Kanai M, Schlunk C, Wang L, Yao JC, Wu TT, Huang S and Xie K: Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res 65: 2746-2754, 2005.
47. Ohnishi S, Ohnami S, Laub F, Aoki K, Suzuki K, Kanai Y, Haga K, Asaka M, Ramirez F and Yoshida T: Downregulation and growth inhibitory effect of epithelial-type Krüppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun 308: 251-256, 2003.
48. Wei D, Kanai M, Jia Z, Le X and Xie K: Kruppel-like factor 4 induces p27Kip1 expression and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res 68: 4631-4639, 2008.
49. Katz JP, Perreault N, Goldstein BG, Lee CS, Labosky PA, Yang VW and Kaestner KH: The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development 129: 2619-2628, 2002.
50. Ghaeb AM, McConnell BB, Nandam MO, Katz JP, Kaestner KH and Yang VW: Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res 67: 7147-7154, 2007.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.